Navigation Links
Wayne State University to study novel treatment for antibiotic-resistant bacteria
Date:11/16/2011

DETROIT The bacteria Enterococcus can cause infections that typically target the digestive tract or bowel; if the bacteria spread, an abdominal abscess or urinary infection could result. Enterococcus also can invade the bloodstream, leading to meningitis, pneumonia or endocarditis an infection of the heart valve. Typically the only people who become ill from this bacteria are the elderly and those who already have health issues, such as diabetes or chronic kidney failure. Enterococcus infections can be serious in these populations.

The bacteria are resistant to a number of antibiotics, but in the past, physicians were able to effectively treat Enterococcus infections with the drug vancomycin. However, during recent years, Enterococcus has become resistant to vancomycin treatment, and the new strain, known as vancomycin-resistant Enterococcus (VRE), is resistant to other antibiotics as well. It also is able to transfer its treatment-resistance abilities to unrelated bacteria such as MRSA or methicillin-resistant Staphylococcus aureus.

Researchers at Wayne State University recently received funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to study a novel antibiotic that may treat VRE infection and decrease mortality. This nearly $430,000 grant led by Michael J. Rybak, Pharm.D., M.P.H., professor of pharmacy practice and director of the Anti-Infective Research Laboratory in WSU's Eugene Applebaum College of Pharmacy and Health Sciences, will provide a better understanding and treatment of this infectious disease.

According to Rybak, daptomycin, a novel lipopeptide antibiotic, shows great promise as a new therapy for VRE infections. "This research study aims to define the dose exposure breakpoint required for daptomycin to ultimately optimize patient response to treatment and prevent the emergence of resistance," he said.

Once Rybak and his team determine the optimal doses of daptomycin, the result will be greater bactericidal activity, prevention of resistance and preservation of daptomycin as a viable antibiotic for continued clinical use.


'/>"/>

Contact: Julie O'Connor
julie.oconnor@gmail.com
313-577-8845
Wayne State University - Office of the Vice President for Research
Source:Eurekalert

Related medicine news :

1. Wayne State therapeutic marijuana use study could impact state policies, guide treatment
2. Wayne State creating computer-based drug intervention for at-risk post-partum women
3. Wayne State to develop a computer-delivered intervention for alcohol use during pregnancy
4. Wayne State University study of heroin users to examine links between stress, drug use
5. Wayne State University to study effects of risky family environments on childhood asthma
6. Wayne State researcher developing treatments for Parkinsons with aid of $2.15 million NIH grant
7. Wayne State University study aims to improve diabetes management in high-risk youth
8. Wayne State University partners with Toyota on safety research
9. Wayne State University researcher to study spinal muscular atrophy
10. Wayne State University awarded $3 million from NIH to foster science and research careers
11. Wayne State researcher receives NSF award to develop neural implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... Miami native and local periodontist Dr. John Paul ... never imagined back in 1991 that this journey would have taken me into so ... 25 years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally recognized ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... agile ecosystem and domain expertise for sponsors and CROs to speed clinical ... supply management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... attempts to compare student test score performance for the 2015-16 school year across ... state’s voucher programs. Though it highlights important patterns in student test score performance, ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical ... partners to help with process innovation in drug formulation and manufacturing. CoreRx ... with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)...  Astute Medical, Inc., developer of biomarkers for better ... at the 2017 National Kidney Foundation (NKF) Spring ... April 22. Physicians will present data on two biomarkers, ... for acute kidney injury (AKI) during the management of ... Elevated levels of TIMP-2 and IGFBP-7 have been ...
Breaking Medicine Technology: